Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC40 (Denifanstat) in Moderate to Severe Acne Vulgaris
NCT06192264Phase 3Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Jan 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of denifanstat in acne vulgaris, sponsored by Ascletis Pharma Inc.. Started Jan 2024; status: completed.
02
Drugs
denifanstat
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT06192264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06192264.